- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00909259
Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing
The purpose of this feasibility study is to determine the effect of stimulating the phrenic nerve to treat periodic breathing (a pattern of breathing characterized by hyperpneas followed by hypopneas or apneas). Clinically, these physiologic events translate into sleep fragmentation, excessive daytime sleepiness, reduced exercise capacity, and possibly ventricular arrhythmias.
Stage 1 of the study is acute in nature, such that subjects will undergo the placement of a stimulation lead, followed by assessment of stimulation of the phrenic nerve using the lead for up to 2 nights of sleep. A sensing lead may also be placed during the initial implant procedure. Observational data will be obtained and stimulation provided using an externalized system connected to the study leads. Following the study, all investigational components will be removed from the patient.
Stage 2 of the study is being conducted at one of the participating sites to determine the initial safety of chronic stimulation of the phrenic nerve in a limited number of patients with sleep disordered breathing. It is anticipated that data obtained in this feasibility study will show that the proposed intervention can modify respiration with a low incidence of adverse effects. The results of this trial are intended to be used to develop a subsequent protocol for a multi-center study of chronic phrenic nerve pacing.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nanjing, China
- Jiangsu Province Hospital
-
-
-
-
-
Wroclaw, Poland
- Polish Military Hospital
-
-
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- Hennepin County Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States
- Ohio Heart Hospital
-
Columbus, Ohio, United States
- The Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is 18 years of age or older
- Patient has a demonstrated history of periodic breathing (symptoms may include sleep fragmentation, as reported by patient or as witnessed by another person, night arousal after apneic episodes, reduced exercise capacity, and daytime sleepiness)
- Patient is expected to be able to tolerate the procedure and remain clinically stable for the duration of the study (e.g. the subject is able to lie down long enough to insert the lead(s) without shortness of breath and the subject is able to tolerate instrumentation during study).
- Patient or their legal representative is willing and able to sign an IRB/MEC approved informed consent (and a privacy protection authorization in the United States)
Exclusion Criteria:
- Baseline oxygen saturation less than or equal to 90% on a stable FIO2
- Evidence of phrenic nerve palsy
- Temperature > 38.0 degrees Celsius
- Inability to place catheter (e.g. previously known coagulopathy, distorted anatomy, etc.)
- Patient is currently enrolled in another study that may confound the results of this study
- Patient for whom informed consent cannot be obtained
- Patient who is pregnant or of child bearing potential without a negative pregnancy test within 10 days of the study procedure
- Patients implanted with a pacemaker, implantable defibrillator, or cardiac resynchronization device who are unable to tolerate turning off the device for the duration of the system testing procedure (based on medical judgment)
- Patients with severe COPD (per GOLD scale)
- Patients with a history of myocardial infarction within 6 months prior to the study
- Patients with unstable angina
- Patients who are intolerant of or allergic to contrast dye
- Patients who are contraindicated for <1mg of steroid (on the stimulation lead).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phrenic Stimulation
|
In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation.
A second lead may also be placed for sensing purposes.
The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment.
Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment.
In Stage 2, a stimulation device and lead will be permanently implanted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary goal of this feasibility study is to show an acute improvement in respiration.
Time Frame: Acute (up to 2 nights of sleep)
|
Acute (up to 2 nights of sleep)
|
The primary safety endpoint of the study is the absence of adverse events related to stimulation that result in hospitalization, the prolongation of an existing hospitalization, or death of the patient.
Time Frame: Acute (up to 2 nights of sleep) plus post-operative assessment at one week (5-10 days) or until resolution of an observed adverse event.
|
Acute (up to 2 nights of sleep) plus post-operative assessment at one week (5-10 days) or until resolution of an observed adverse event.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterization of chronic safety of stimulating the phrenic nerve (Stage 2 of study).
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Zhang XL, Ding N, Wang H, Augostini R, Yang B, Xu D, Ju W, Hou X, Li X, Ni B, Cao K, George I, Wang J, Zhang SJ. Transvenous phrenic nerve stimulation in patients with Cheyne-Stokes respiration and congestive heart failure: a safety and proof-of-concept study. Chest. 2012 Oct;142(4):927-934. doi: 10.1378/chest.11-1899.
- Ponikowski P, Javaheri S, Michalkiewicz D, Bart BA, Czarnecka D, Jastrzebski M, Kusiak A, Augostini R, Jagielski D, Witkowski T, Khayat RN, Oldenburg O, Gutleben KJ, Bitter T, Karim R, Iber C, Hasan A, Hibler K, Germany R, Abraham WT. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J. 2012 Apr;33(7):889-94. doi: 10.1093/eurheartj/ehr298. Epub 2011 Aug 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCI-Feasibility
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cheyne-Stokes Respiration
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of OsloResMedCompletedHeart Failure | Cheyne Stokes RespirationNorway
-
ResMedCompletedSubstudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation (MS)Heart Failure | Sleep Disorder | Cheyne Stokes RespirationAustralia, Germany, Switzerland, Netherlands, France, Finland, Czech Republic, United Kingdom
-
Respicardia, Inc.CompletedSleep Apnea | Sleep Disordered Breathing | Periodic Breathing | Central Sleep Apnea | Cheyne Stokes RespirationUnited States, Poland, Germany, Italy
-
Umeå UniversitySwedish Heart Lung FoundationCompleted
-
ResMedCompletedCheyne-Stokes Respiration | Periodic BreathingGermany
-
Heart and Diabetes Center North-Rhine WestfaliaCompletedObstructive Sleep Apnoea | Cheyne Stokes Respiration | Central Sleep ApnoeaGermany
-
Umeå UniversityCompleted
-
ResMedCompletedCheyne-Stokes Respiration | Heart Failure, CongestiveAustralia
-
Heart and Diabetes Center North-Rhine WestfaliaTerminatedHigh-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure (FLOAT-CS)Heart Failure,CongestiveGermany
Clinical Trials on Phrenic stimulation device
-
University Hospital, AngersNot yet recruitingMechanical VentilationFrance
-
Luzerner KantonsspitalInovise MedicalCompletedHeart Failure, Congestive | Transcutaneous Electric Nerve Stimulation | Cardiac Pacing, ArtificialSwitzerland
-
Swiss Federal Institute of TechnologyActive, not recruiting
-
University Hospital, MontpellierCompletedCritical Illness Myopathy | Respiratory ParalysisFrance
-
Bing SunRecruitingMechanical Ventilation | WeaningChina
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Seoul National University HospitalNational Research Foundation of KoreaCompletedElectrical Stimulation | Phrenic NerveKorea, Republic of
-
Swiss Federal Institute of TechnologyCompleted
-
Association pour le Développement et l'Organisation...Completed
-
Hospital Sirio-LibanesHospital Israelita Albert EinsteinRecruiting